The objective of this study is to enhance the safety profile of SAbR in ultra-central tumors of the lung (primary or metastatic) without compromising its effectiveness.

开始日期2025-09-19

申办/合作机构

The University of Texas Southwestern Medical Center

[+1]

NCT06638541

/ RecruitingN/AIIT

Dose dE-eScalaTion IN prostATe radIOtherapy usiNg an MR-Linac in 2 Fractions - a Randomised Trial

DESTINATION 2 is a multi-centre randomised trial treating intermediate risk localised prostate cancer with 2 fraction Stereotactic Body Radiotherapy (SBRT). All radiotherapy will be delivered in two fractions (sessions) on an MR Linac using daily adaptation. Men will either receive uniform dose radiotherapy or de-escalated dose radiotherapy. The primary endpoint is acute GU CTCAE v5 grade 2+ toxicity. It will also look at late toxicity, patient-reported outcome measures and PSA control.

开始日期2025-01-20

申办/合作机构

Royal Marsden NHS Foundation Trust

[+2]

NCT06130280

/ Recruiting临床2期IIT

Ablative Dose Single Fraction MRguided Colorectal Liver Metastasis SBRT

The researchers are doing this study to see if one session of high-dose contrast-enhanced MRI-guided SBRT (stereotactic body radiation therapy) is effective for colorectal cancer that has spread to the liver. The researchers will evaluate how well the study treatment can prevent the liver metastasis from growing and spreading. In addition, they will see whether it causes any side effects and whether there are any characteristics of the research MRI images that can predict response to treatment.

开始日期2023-11-08

申办/合作机构

Memorial Sloan Kettering Cancer Center

[+1]

100 项与 Elekta AB 相关的临床结果

登录后查看更多信息

0 项与 Elekta AB 相关的专利（医药）

登录后查看更多信息

项与 Elekta AB 相关的文献（医药）

2025-03-16·PHYSICS IN MEDICINE AND BIOLOGY

IPEM code of practice for proton therapy dosimetry based on the NPL primary standard proton calorimeter calibration service

Article

作者: Van Den Heuvel, Frank ; Fiorini, Francesca ; Green, Stuart ; Palmans, Hugo ; Pettingell, John ; Souza, Derek D' ; Amos, Richard A ; Lourenço, Ana ; Thomas, Russell ; Lee, Nigel ; Kacperek, Andrzej ; Mackay, Ranald

Abstract:

Internationally, reference dosimetry for clinical proton beams largely follows the guidelines published by the International Atomic Energy Agency (IAEA TRS-398 Rev. 1 (2024). This approach yields a relative standard uncertainty of 1.7% (k = 1) on the absorbed dose to water determined under reference conditions. The new IPEM code of practice presented here, enables the relative standard uncertainty on the absorbed dose to water measured under reference conditions to be reduced to 1.0% (k = 1). This improvement is based on the absorbed dose to water calibration service for proton beams provided by the National Physical Laboratory (NPL), the UK’s primary standards laboratory. This significantly reduced uncertainty is achieved through the use of a primary standard level graphite calorimeter to derive absorbed dose to water directly in the clinical department’s beam. This eliminates the need for beam quality correction factors (kQ,Q0) as required by the IAEA TRS-398 approach. The portable primary standard level graphite calorimeter, developed over a number of years at the NPL, is sufficiently robust to be useable in the proton beams of clinical facilities both in the UK and overseas. The new code of practice involves performing reference dosimetry measurements directly traceable to the primary standard level graphite calorimeter in a clinical proton beam. Calibration of an ionisation chamber is performed in the centre of a standard test volume (STV) of dose, defined here to be a 10 × 10 × 10 cm volume in water, centred at a depth of 15 cm. Further STVs at reduced and increased depths are also utilised. The designated ionisation chambers are Roos-type plane-parallel chambers. This article provides all the necessary background material, formalism, and specifications of reference conditions required to implement reference dosimetry according to this new code of practice. The Annexes provide a detailed review of ion recombination and how this should be assessed (Annex A1) and detailed work instructions for creating and delivering the STVs (Annex A2).

2025-01-19·PHYSICS IN MEDICINE AND BIOLOGY

On the correction factors for small field dosimetry in 1.5T MR-linacs

Article

作者: Iosif, Andreas ; Koutsouveli, Efi ; Karaiskos, Pantelis ; Margaroni, Vasiliki ; Episkopakis, Anastasios ; Pappas, Eleftherios P

Abstract:

Objective. Clinical dosimetry in the presence of a 1.5 T magnetic field is challenging, let alone in case small fields are involved. The scope of this study is to determine a set of relevant correction factors for a variety of MR-compatible detectors with emphasis on small fields. Two dosimetry formalisms adopted from the literature are considered. Approach. Six small-cavity ionization chambers (from three manufacturers), four active solid-state detectors and a thermoluminescence dosimeter microcube were modeled in the EGSnrc Monte Carlo code. Phase space files for field sizes down to 1 × 1 cm2 of the Unity 1.5 T/7 MV MR-linac (Elekta, UK) were used as source models. Simulations were performed to calculate the kQB,QfB,f (also known as kB,Q), kQmsrB,fmsr and kQclin,QmsrB,fclin,fmsr relevant to two different dosimetry formalisms. Two detector orientations with respect to the magnetic field were considered. Moreover, the effect of the ionization chamber’s stem length (a construction parameter) on the correction factor was investigated. Simulations were also carried out to determine whether correction factors obtained in water can be applied in dosimetry procedures involving water-equivalent solid phantoms. Main results. Under the kQB,QfB,f-based formalism, the required corrections to ionization chamber responses did not exceed 1.5% even for the smallest field size considered. A much wider range of kQB,QfB,f values was obtained for the active solid-state detectors included in the simulations. This is the first study to report kQclin,QmsrB,fclin,fmsr values for ionization chambers. The impact of the stem on correction factors is not significant for lengths ⩾0.75 cm. Correction factors determined in water are also valid in dosimetry protocols employing solid phantoms. Significance. This work substantially expands the range of available detectors that can be used in small field dosimetry, enabling more options for commissioning, beam modeling and quality assurance procedures in 1.5 T MR-Linacs. However, more studies are needed to establish a complete and reliable dataset.

2024-11-01·Brachytherapy

Gynecological brachytherapy hybrid training: The Tata Memorial Centre and BrachyAcademy experience

Article

作者: Chopra, Supriya ; Tanderup, Kari ; Jain, Jeevanshu ; Gupta, Ankita ; Dizendorf, Elena ; Panda, Subhajit ; Upreti, Ritu Raj ; Bhavke, Akshay ; Nout, Remi ; Sturdza, Alina ; Tharavichitkul, Ekkasit ; Tatli, Hamza ; Agarwal, Jai Prakash ; Chargari, Cyrus ; Mittal, Prachi ; Kohle, Satish ; Ghadi, Yogesh ; Bhajbhuje, Rajesh ; Jeeva, Meenakshi

PURPOSE:

The lack of training is a significant barrier to practicing brachytherapy (BT). Tata Memorial Centre, alongside international BT experts and BrachyAcademy, developed a hybrid gynecological BT training module. This study outlines the preparation, organization, and execution of the 2022-2023 Mumbai training, evaluates its effectiveness, and highlights areas for improvement.

MATERIALS AND METHODS:

Participants were radiation oncologists (RO) and medical physicists (MP) with experience in gynecological BT aiming to transition to image-guided brachytherapy (IGBT). The training covered cervical, endometrial, vaginal, vulvar, periurethral cancers, and pelvic reirradiation. The hybrid course included online pre and postcourse homework assignments, a live workshop with hands-on training, a 6-month online follow-up, and a 12-month opportunity to share the transition experience.

RESULTS:

The December 2022 Mumbai live workshop spanned 2.5 days, attracting 39 participants from 8 countries (Asia, Africa, Australia/Oceania). Feedback rated the course 9/10, with 78% fully meeting expectations. Forty-four percent suggested extending hands-on training. At the 6-month follow-up, response rates were low (33% RO, 11% MP). Among responding RO, 70% reported practice changes after attending the course, 40% implemented IGBT concepts in clinical practice, and 50% increased confidence in image-guided procedures. Overall, 45% of respondent sites could strengthen their intracavitary/interstitial program, while others faced limitations due to lack of access to advanced BT applicators.

CONCLUSION:

The hybrid gynecological BT training concept was successfully executed. Areas for improvement include extending hands-on training and enhancing participant engagement postcourse. Structured steps beyond training may be needed to improve the utilization of advanced brachytherapy for gynecological cancers.

112

项与 Elekta AB 相关的新闻（医药）

2026-01-07

·Business Wire

Sensus Healthcare Appoints Larry Biscotti to its Board of Directors

BOCA RATON, Fla.--(BUSINESS WIRE)--Sensus Healthcare, Inc. (Nasdaq: SRTS), a medical device company specializing in highly effective, non-invasive, minimally-invasive and cost-effective treatments for oncological and non-oncological skin conditions, today announced the appointment of Larry Biscotti to its Board of Directors, effective immediately. With this appointment the Sensus Healthcare Board has six Directors, including four independent Directors. Mr. Biscotti brings more than 25 years of executive leadership experience in the medical device and healthcare technology sectors, with an extensive background in driving commercial strategy, expanding global market share and launching advanced imaging and oncology technologies. He currently serves as President, Imaging for the U.S. and Canada at GE HealthCare, where he is responsible for the company’s largest global product and solutions segment. His prior work history includes positions with Elekta, Varian Medical Systems, Toshiba Medical, SMV Nuclear Medicine, and CTI Molecular Imaging, providing a strong foundation in imaging, oncology and radiation therapy technologies. “Larry brings to the Sensus Board a wealth of skills, value and complementary experiences. Over the course of his career, he has led multibillion-dollar P&Ls, introduced innovative cancer treatment technologies, built and scaled commercial teams and expanded businesses globally through strategic partnerships and distribution agreements,” said Joe Sardano, Chairman and Chief Executive Officer of Sensus Healthcare. “His integrity, judgment and commitment to improving patient outcomes fit well with our culture and mission. I’ve had the privilege of working with Larry throughout my career and know firsthand the leadership and insight he brings. We are pleased to welcome Larry to our Board as we expand the reach of our SRT technology and execute on our long-term vision.” “I am honored to join the Board of Directors of Sensus Healthcare at a time when patient-centered, non-invasive treatments are becoming increasingly important for a variety of conditions. The company’s commitment to innovation, clinical excellence and improving patient outcomes strongly aligns with my own personal values and professional experiences. I look forward to supporting Sensus’ continued growth and impact for patients and clinicians,” added Mr. Biscotti. Mr. Biscotti holds an MBA from Pepperdine University and a Bachelor of Science from Cornell University. He is an alumnus of Harvard Business School’s Program for Leadership Development. About Sensus Healthcare Sensus Healthcare, Inc. is a global pioneer in the development and delivery of non-invasive treatments for skin cancer and keloids. Leveraging its cutting-edge superficial radiotherapy (SRT and IG-SRT) technology, the company provides healthcare providers with a highly effective, patient-centric treatment platform. With a dedication to driving innovation in radiation oncology, Sensus Healthcare offers solutions that are safe, precise, and adaptable to a variety of clinical settings. For more information, please visit www.sensushealthcare.com.

高管变更放射疗法

2026-01-05

·国家药品监督管理局

医科达系统有限公司Elekta Solutions AB 对放射治疗临床管理软件Oncology Information System主动召回

索引号 JGXX-2026-10001 主题分类监管信息 / 责令召回信息标题医科达系统有限公司Elekta Solutions AB 对放射治疗临床管理软件Oncology Information System主动召回发布日期 2026-01-05医科达（上海）医疗器械有限公司报告，由于发现部分境外受影响的放射治疗临床管理软件，在手动记录部分治疗记录后，可能出现不正确的剂量。因此医科达决定主动对所有受影响的放射治疗临床管理软件（国械注进20173210587）主动召回。召回级别为三级召回。本次召回涉及的产品未进口至中国，具体型号、规格及批次等详细信息见《医疗器械召回事件报告表》。附件：医疗器械召回事件报告表 2026年1月5日医科达（上海）医疗器械有限公司召回报表.pdf

放射疗法

2025-12-29

·今日头条

欧洲药企涌进中国：困境下的战略选择

欧洲药企正加速将业务重心转向中国。丹麦雅赛利制药关闭了哥本哈根的最大工厂，计划十年内将抗感染产品转移至中国；世界三大药企之一的诺华致信欧盟委员会，警告若不提高药价，药物临床试验和研发会进一步向中美转移。欧洲医药行业的困境由来已久：欧盟对药物价格的严格管制压制了专利药增长，能源和人力成本持续飙升，环保法规加剧了生产负担，而医疗系统对药价上涨的抵触让药企陷入持续亏损。相比之下，中国的医药市场展现出独特优势——全球80%以上的活性药物成分原料来自中国，形成了从原料到制剂再到包装的完整产业链；庞大的市场需求支撑企业规模效应；鼓励创新的政策让中国创新药获批速度大幅提升，十四五以来累计113个创新药上市，2024年获批48个1类创新药，仅比美国少2个。外资药企纷纷加码中国布局：阿斯利康宣布未来五年25亿美元投资计划，在北京建立第六个全球战略研发中心，预计员工增至1700人；赛诺菲投资10亿欧元在北京建胰岛素原料药项目，还与凯辉基金设立20亿元医药创新基金；诺和诺德连续8年参加进博会，把研发阶段的全球首个基础胰岛素/GLP-1RA周制剂IcoSema带到展会上，该产品去年12月已提交中国上市申请。进博会成为外资药企连接中国市场的重要平台，诺和诺德第六届进博会展出的体重管理GLP-1RA周制剂，7个月后就获批上市。研发合作也在不断深化：GSK超过80%的中国研发项目并入全球同步开发，未来3年约18项新产品及新适应证将在中国获批；医科达在上海的软件研发中心占全球相关研发力量的50%，还帮助中国培养放疗技术人才；恒瑞医药将HRS-9821项目全球独家权利授予GSK，成为国产创新药融入全球产业体系的标杆。在免疫药物这个蓝海市场，赛诺菲的布局尤为积极。其度普利尤单抗通过博鳌乐城先行先试政策快速上市，成为业绩增长引擎；新款免疫疗法Teplizumab获批在乐城先行先试，用于延缓1型糖尿病进展。为解决医疗资源分布不均问题，赛诺菲与北京大学血液病研究所合作，推动造血干细胞移植规范化诊疗和全程管理均质化。中国已成为阿斯利康、赛诺菲等企业的第二大市场——阿斯利康2024年中国区营收64亿美元，占全球12%；赛诺菲2023年中国销售额29.12亿欧元，2024年一季度同比增长6.2%。对欧洲药企而言，中国不仅是摆脱亏损的救命稻草，更是实现创新增长的核心战场，这里的产业链、市场和政策，正在成为全球医药行业的新引擎。

免疫疗法上市批准

100 项与 Elekta AB 相关的药物交易

登录后查看更多信息

100 项与 Elekta AB 相关的转化医学

登录后查看更多信息